Balyasny Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Balyasny Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,212,745	Closed	-$256M	–	3046
2023 Q3	$256M	Buy	2,212,745 +848,150	+62%	+$91.1M	0.52%	19
2023 Q2	$140M	Buy	1,364,595 +502,189	+58%	+$53M	0.31%	55
2023 Q1	$94.1M	Sell	862,406 -741,412	-46%	-$82M	0.24%	95
2022 Q4	$183M	Buy	1,603,818 +440,287	+38%	+$36.6M	0.5%	13
2022 Q3	$72M	Buy	+1,163,531	New	+$81.3M	0.22%	95
2021 Q3	–	Sell	-366,372	Closed	-$34.3M	–	2675
2021 Q2	$34.3M	Buy	366,372 +299,979	+452%	+$27.6M	0.16%	149
2021 Q1	$6.11M	Buy	+66,393	New	+$5.6M	0.03%	630
2020 Q4	–	Sell	-178,635	Closed	-$13.9M	–	1887
2020 Q3	$13.9M	Buy	178,635 +123,042	+221%	+$8.47M	0.1%	291
2020 Q2	$3.09M	Sell	55,593 -411,656	-88%	-$17.6M	0.03%	630
2020 Q1	$13.8M	Sell	467,249 -488,028	-51%	-$16.5M	0.16%	177
2019 Q4	$34.6M	Buy	955,277 +675,840	+242%	+$20.7M	0.21%	141
2019 Q3	$7.61M	Sell	279,437 -570,560	-67%	-$14.8M	0.05%	469
2019 Q2	$20.5M	Buy	849,997 +324,497	+62%	+$8.23M	0.13%	217
2019 Q1	$13.9M	Sell	525,500 -340,523	-39%	-$8.07M	0.09%	307
2018 Q4	$16.9M	Buy	866,023 +536,770	+163%	+$10.5M	0.12%	240
2018 Q3	$6.45M	Buy	329,253 +260,313	+378%	+$4.95M	0.03%	618
2018 Q2	$1.14M	Sell	68,940 -121,278	-64%	-$1.85M	0.01%	1085
2018 Q1	$2.7M	Sell	190,218 -935,295	-83%	-$13.8M	0.01%	902
2017 Q4	$16.4M	Buy	1,125,513 +1,033,313	+1,121%	+$14.5M	0.05%	476
2017 Q3	$1.17M	Sell	92,200 -1,083,739	-92%	-$13.8M	﹤0.01%	1125
2017 Q2	$14M	Buy	+1,175,939	New	+$14.6M	0.06%	426
2017 Q1	–	Sell	-29,984	Closed	-$485K	–	1870
2016 Q4	$485K	Buy	+29,984	New	+$544K	﹤0.01%	1151
2016 Q3	–	Sell	-534,640	Closed	-$8.81M	–	1398
2016 Q2	$8.81M	Buy	534,640 +524,610	+5,230%	+$8.49M	0.06%	390
2016 Q1	$166K	Buy	+10,030	New	+$175K	﹤0.01%	1151

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's HZNP Position: Q4 2023 in Review

Balyasny Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,212,745 shares — an estimated $256M sold.

Balyasny Asset Management first reported a position in HZNP in Q1 2016 and held it in 24 quarters. The position peaked at $256M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Balyasny Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Balyasny Asset Management sold 2,212,745 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $256M.
Balyasny Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and held it in 24 quarters.
Balyasny Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $256M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.